An advisory panel at FDA has voted to recommend Evenity, an osteoporosis treatment co-developed with Belgium-based UCB. The positive opinion reflects a successful Phase III clinical trial conducted by Amgen to assess the product on a sample of patients with osteoporosis: fracture risk was reduced by 50%.
Remarkably, the new therapy is reported to have caused heart issues in the same patients. Once approved, Evenity has potential to generate as much as $479m in the US, RBC Capital Markets’ analysts say.
(Source: Investor’s Business Daily)